Merck, Inc.
🇺🇸United States
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 218
- Registration Number
- NCT02105662
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- Drug: Placebo to Grazoprevir / Elbasvir 50 mg FDC
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 421
- Registration Number
- NCT02105467
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)
Phase 2
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 79
- Registration Number
- NCT02105454
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 301
- Registration Number
- NCT02105688
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Biological: Insulin Glargine Rescue Medication
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1233
- Registration Number
- NCT02099110
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
Phase 2
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 237
- Registration Number
- NCT02092350
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 205
- Registration Number
- NCT02092285
- Locations
- 🇬🇧
Merck Sharp & Dohme Ltd., Hoddesdon, United Kingdom
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02089659
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Phase 1
Completed
- Conditions
- Renal Cell CarcinomaMelanoma
- Interventions
- Biological: PembrolizumabBiological: PegIFN-2bBiological: Ipilimumab
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 295
- Registration Number
- NCT02089685
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
- Conditions
- Melanoma
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02083484
© Copyright 2025. All Rights Reserved by MedPath